t of the cyclin-dependent Correlated-dependent kinase inhibitors, second The first phase Use study of 29 patients defined dose in subsequent studies and showed the toxicity of t Certain medications, such as muscle pain, Hypertriglycerid Chemistry and curves Sen thromboembolism especially in 7 of 21 patients unscreened for factors observed thrombophilia. an sp Lower time GSK690693 Best test for 33 HCC patients These preferential toxicity Tsprofil and demonstrated T Cytostatic activity primarily in this type of cancer. In fact, no objective responses were w During treatment received, although 57 of the patients showed disease stabilization in the L Length, with a survival rate of 19.2 overall very interesting month. surprisingly showed two patients sp-run reaction. after drug treatment, which seems to be a distinct feature of TAC 101 Unfortunately, a randomized international phase Trial comparing TAC was 101 compared to placebo in patients with pre Sorafenib HCC recently recruiting because of the occurrence of an Unweighted Similar high incidence of thromboembolic events is closed.
It is therefore possible to change that these events were already observed in the early stages of development, significantly slow k Nnte the development CYT997 of which, however, a connection is potentially very interesting, at least in HCC. The hepatocyte growth factor pathway CC Met Met, a receptor tyrosine kinase, is currently the only known receptor for HGF, also known as scatter factor. Binding of HGF with the extracellular Ren Dom ne The high affinity receptor Met C causes a multimerization of the receptor itself and phosphorylation of several tyrosine residues resulting in the intracellular Ren part is C, and Met, leads ultimately to signal transduction in the cell nucleus. This way regulates several biological events that are heavily involved in the development of cancer.
To go Ren the emergence of invasive Ph Genotype, the stimulation of mitogenic and motogenic activity of t, Erh Hte resistance to apoptosis and increased Hte angiogenesis. It is therefore easy to understand how such a path is often confinement in a number of human tumors, Deregulated Lich HCC. ARQ 197 is a very exciting first in class compound that selectively inhibits C Met is currently in some of the clinical evaluation in a randomized, placebo-controlled Phase , Study patients with HCC treated with sorafenib pre. Molecular targets AGENTS AND EVALUATION OF RESPONSE The response evaluation is undoubtedly one of the main problems Schwellenl Change h with the use of ever More frequently new molecular targeted drugs. As can be seen, in gastrointestinal stromal tumors initially treated with imatinib and in phase Sorafenib HCC study in herk Mmlichen response criteria in oncology, WHO RECIST criteria, which were originally developed to herk the reaction Judge mmlichen chemotherapeutics, are difficult to use molecular targeted agents hav